drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00247 | DB00673 | 1,131 | 723 | [
"DDInter1194",
"DDInter112"
] | Methysergide | Aprepitant | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1131,
24,
723
]
],
[
[
1131,
21,
28898
],
[
28898,
60,
723
]
],
[
[
1131,
24,
222
],
[
222,
62,
723
]
],
[
[
1131,
24,
1101
],
[
1101,... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effec... | Methysergide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Aprepitant (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken wi... |
DB00041 | DB15822 | 1,648 | 69 | [
"DDInter38",
"DDInter1504"
] | Aldesleukin | Pralsetinib | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
1648,
24,
69
]
],
[
[
1648,
24,
322
],
[
322,
24,
69
]
],
[
[
1648,
63,
305
],
[
305,
24,
69
]
],
[
[
1648,
25,
1377
],
[
1377,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Esche... |
DB00408 | DB04837 | 1,408 | 649 | [
"DDInter1099",
"DDInter407"
] | Loxapine | Clofedanol | An antipsychotic agent used in schizophrenia. [PubChem] | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1408,
24,
649
]
],
[
[
1408,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1408,
24,
832
],
[
832,
40,
649
]
],
[
[
1408,
63,
701
],
[
701,
... | [
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Loxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine ... |
DB09570 | DB14568 | 1,480 | 982 | [
"DDInter1002",
"DDInter1000"
] | Ixazomib | Ivosidenib | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1480,
24,
982
]
],
[
[
1480,
63,
112
],
[
112,
23,
982
]
],
[
[
1480,
64,
976
],
[
976,
24,
982
]
],
[
[
1480,
63,
700
],
[
700,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ixazomib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may caus... |
DB12364 | DB15982 | 1,421 | 1,339 | [
"DDInter200",
"DDInter193"
] | Betrixaban | Berotralstat | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity. Betrixaban, now developed by Portola Pharmaceuticals In... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
1421,
24,
1339
]
],
[
[
1421,
63,
222
],
[
222,
23,
1339
]
],
[
[
1421,
25,
283
],
[
283,
23,
1339
]
],
[
[
1421,
64,
1213
],
[
1213,
... | [
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Betrixaban may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may caus... |
DB00222 | DB00758 | 245 | 1,347 | [
"DDInter825",
"DDInter413"
] | Glimepiride | Clopidogrel | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Minor | 0 | [
[
[
245,
23,
1347
]
],
[
[
245,
6,
6017
],
[
6017,
45,
1347
]
],
[
[
245,
21,
28778
],
[
28778,
60,
1347
]
],
[
[
245,
63,
1028
],
[
1028,... | [
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
]
],
[
[
"Glimepiride",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Clopidogrel (Compound)
Glimepiride (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Clopidogrel (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01219 | DB06282 | 716 | 516 | [
"DDInter473",
"DDInter1053"
] | Dantrolene | Levocetirizine | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
716,
24,
516
]
],
[
[
716,
63,
701
],
[
701,
24,
516
]
],
[
[
716,
24,
407
],
[
407,
63,
516
]
],
[
[
716,
24,
649
],
[
649,
24,... | [
[
[
"Dantrolene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Dantrolene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Dantrolene may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Dantrolene may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium m... |
DB00978 | DB11093 | 739 | 636 | [
"DDInter1084",
"DDInter273"
] | Lomefloxacin | Calcium citrate | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
739,
24,
636
]
],
[
[
739,
40,
1299
],
[
1299,
24,
636
]
],
[
[
739,
1,
1539
],
[
1539,
24,
636
]
],
[
[
739,
24,
115
],
[
115,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may ... | Lomefloxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Lomefloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB10583 | DB11730 | 949 | 351 | [
"DDInter415",
"DDInter1588"
] | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Ribociclib | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
949,
24,
351
]
],
[
[
949,
63,
310
],
[
310,
24,
351
]
],
[
[
949,
24,
738
],
[
738,
63,
351
]
],
[
[
949,
24,
1259
],
[
1259,
6... | [
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate... | Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Clostridium tetani toxoid antigen (formaldehyde inactivated)... |
DB01238 | DB08875 | 673 | 1,618 | [
"DDInter118",
"DDInter262"
] | Aripiprazole | Cabozantinib | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
673,
24,
1618
]
],
[
[
673,
62,
112
],
[
112,
23,
1618
]
],
[
[
673,
63,
723
],
[
723,
24,
1618
]
],
[
[
673,
24,
384
],
[
384,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant an... |
DB00206 | DB00222 | 1,245 | 245 | [
"DDInter1582",
"DDInter825"
] | Reserpine | Glimepiride | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Moderate | 1 | [
[
[
1245,
24,
245
]
],
[
[
1245,
24,
959
],
[
959,
1,
245
]
],
[
[
1245,
21,
29209
],
[
29209,
60,
245
]
],
[
[
1245,
24,
708
],
[
708,
... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Reserpine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Glimepiride (Compound)
Reserpine may cause a moderate interaction that ... |
DB00011 | DB01229 | 1,451 | 973 | [
"DDInter944",
"DDInter1377"
] | Interferon alfa-n1 | Paclitaxel | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1451,
24,
973
]
],
[
[
1451,
24,
310
],
[
310,
63,
973
]
],
[
[
1451,
24,
134
],
[
134,
24,
973
]
],
[
[
1451,
25,
990
],
[
990,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Vin... |
DB00472 | DB09082 | 758 | 659 | [
"DDInter758",
"DDInter1934"
] | Fluoxetine | Vilanterol | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
758,
24,
659
]
],
[
[
758,
24,
1296
],
[
1296,
63,
659
]
],
[
[
758,
25,
1069
],
[
1069,
24,
659
]
],
[
[
758,
24,
959
],
[
959,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Fluoxetine may lead to a major life threatening interaction when taken with Vandetanib and Vandetani... |
DB00201 | DB01059 | 1,684 | 956 | [
"DDInter263",
"DDInter1313"
] | Caffeine | Norfloxacin | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Moderate | 1 | [
[
[
1684,
24,
956
]
],
[
[
1684,
23,
1299
],
[
1299,
1,
956
]
],
[
[
1684,
24,
1467
],
[
1467,
1,
956
]
],
[
[
1684,
6,
9842
],
[
9842,
... | [
[
[
"Caffeine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
]
],
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
],
[
... | Caffeine may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin (Compound) resembles Norfloxacin (Compound)
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Norfloxacin (Compound)
Ca... |
DB00758 | DB10897 | 1,347 | 539 | [
"DDInter413",
"DDInter291"
] | Clopidogrel | Capsicum | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1347,
23,
539
]
],
[
[
1347,
24,
885
],
[
885,
23,
539
]
],
[
[
1347,
64,
1018
],
[
1018,
23,
539
]
],
[
[
1347,
25,
1226
],
[
1226,
... | [
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may ca... |
DB06674 | DB09073 | 908 | 951 | [
"DDInter837",
"DDInter1379"
] | Golimumab | Palbociclib | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Major | 2 | [
[
[
908,
25,
951
]
],
[
[
908,
24,
496
],
[
496,
63,
951
]
],
[
[
908,
25,
1476
],
[
1476,
63,
951
]
],
[
[
908,
63,
1454
],
[
1454,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"He... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Golimumab may lead to a major life threatening interaction when taken with Brigatinib and Brig... |
DB00552 | DB11817 | 1,238 | 1,259 | [
"DDInter1425",
"DDInter165"
] | Pentostatin | Baricitinib | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1238,
25,
1259
]
],
[
[
1238,
24,
949
],
[
949,
24,
1259
]
],
[
[
1238,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
1238,
24,
384
],
[
384,
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Pentostati... |
DB00586 | DB12130 | 1,512 | 1,017 | [
"DDInter537",
"DDInter1094"
] | Diclofenac | Lorlatinib | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1512,
24,
1017
]
],
[
[
1512,
63,
590
],
[
590,
24,
1017
]
],
[
[
1512,
24,
175
],
[
175,
24,
1017
]
],
[
[
1512,
25,
1421
],
[
1421,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone a... |
DB00660 | DB01142 | 1,470 | 1,264 | [
"DDInter1163",
"DDInter593"
] | Metaxalone | Doxepin | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1470,
24,
1264
]
],
[
[
1470,
24,
401
],
[
401,
24,
1264
]
],
[
[
1470,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
1470,
24,
649
],
[
649,
... | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxyl... |
DB01126 | DB09098 | 1,260 | 98 | [
"DDInter611",
"DDInter1700"
] | Dutasteride | Somatrem | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1260,
24,
98
]
],
[
[
1260,
1,
284
],
[
284,
24,
98
]
],
[
[
1260,
24,
159
],
[
159,
63,
98
]
],
[
[
1260,
24,
609
],
[
609,
24,... | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dutasteride",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moder... | Dutasteride (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction th... |
DB09054 | DB11575 | 384 | 1,676 | [
"DDInter905",
"DDInter841"
] | Idelalisib | Grazoprevir | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Major | 2 | [
[
[
384,
25,
1676
]
],
[
[
384,
63,
723
],
[
723,
24,
1676
]
],
[
[
384,
64,
1478
],
[
1478,
24,
1676
]
],
[
[
384,
25,
351
],
[
351,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitan... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Idelalisib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a... |
DB06717 | DB09065 | 875 | 760 | [
"DDInter778",
"DDInter424"
] | Fosaprepitant | Cobicistat | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
875,
24,
760
]
],
[
[
875,
62,
1101
],
[
1101,
23,
760
]
],
[
[
875,
40,
723
],
[
723,
24,
760
]
],
[
[
875,
24,
868
],
[
868,
2... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fosaprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
... | Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Fosaprepitant (Compound) resembles Aprepitant (Compound) and Aprepitant may cause a moderate interaction that cou... |
DB00334 | DB00604 | 867 | 1,425 | [
"DDInter1326",
"DDInter385"
] | Olanzapine | Cisapride | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Moderate | 1 | [
[
[
867,
24,
1425
]
],
[
[
867,
25,
1311
],
[
1311,
1,
1425
]
],
[
[
867,
24,
717
],
[
717,
1,
1425
]
],
[
[
867,
6,
6962
],
[
6962,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
]
],
[
[
"Olanzapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclo... | Olanzapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide (Compound) resembles Cisapride (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide (Compound) resembles Cisapride (Compo... |
DB00352 | DB14444 | 482 | 151 | [
"DDInter1814",
"DDInter924"
] | Tioguanine | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
482,
24,
151
]
],
[
[
482,
63,
66
],
[
66,
24,
151
]
],
[
[
482,
24,
134
],
[
134,
24,
151
]
],
[
[
482,
25,
375
],
[
375,
24,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could e... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine may cause a moderate inter... |
DB06290 | DB11760 | 1,449 | 119 | [
"DDInter1673",
"DDInter1742"
] | Simeprevir | Talazoparib | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1449,
24,
119
]
],
[
[
1449,
24,
971
],
[
971,
63,
119
]
],
[
[
1449,
25,
412
],
[
412,
24,
119
]
],
[
[
1449,
63,
467
],
[
467,
... | [
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[... | Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Simeprevir may lead to a major life threatening interaction when taken with Eluxadoline and Eluxadoline may... |
DB01035 | DB11730 | 1,401 | 351 | [
"DDInter1524",
"DDInter1588"
] | Procainamide | Ribociclib | A derivative of procaine with less CNS action. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1401,
25,
351
]
],
[
[
1401,
62,
112
],
[
112,
23,
351
]
],
[
[
1401,
63,
355
],
[
355,
24,
351
]
],
[
[
1401,
24,
259
],
[
259,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Procainamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and L... |
DB00794 | DB08816 | 759 | 578 | [
"DDInter1521",
"DDInter1802"
] | Primidone | Ticagrelor | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Major | 2 | [
[
[
759,
25,
578
]
],
[
[
759,
6,
8374
],
[
8374,
45,
578
]
],
[
[
759,
21,
28646
],
[
28646,
60,
578
]
],
[
[
759,
25,
1135
],
[
1135,
... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelo... | Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Primidone (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Primidone may lead to a ma... |
DB01267 | DB09043 | 519 | 135 | [
"DDInter1381",
"DDInter36"
] | Paliperidone | Albiglutide | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
519,
24,
135
]
],
[
[
519,
63,
1647
],
[
1647,
23,
135
]
],
[
[
519,
63,
870
],
[
870,
24,
135
]
],
[
[
519,
24,
1042
],
[
1042,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fl... |
DB00445 | DB11003 | 322 | 748 | [
"DDInter655",
"DDInter100"
] | Epirubicin | Anthrax vaccine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
322,
24,
748
]
],
[
[
322,
63,
168
],
[
168,
24,
748
]
],
[
[
322,
24,
896
],
[
896,
24,
748
]
],
[
[
322,
24,
564
],
[
564,
63,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Et... |
DB00531 | DB12130 | 450 | 1,017 | [
"DDInter456",
"DDInter1094"
] | Cyclophosphamide | Lorlatinib | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
450,
24,
1017
]
],
[
[
450,
63,
590
],
[
590,
24,
1017
]
],
[
[
450,
25,
976
],
[
976,
24,
1017
]
],
[
[
450,
24,
126
],
[
126,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Cyclophosphamide may lead to a major life threatening interaction when taken with Tofacitinib and To... |
DB00397 | DB01175 | 1,466 | 318 | [
"DDInter1458",
"DDInter672"
] | Phenylpropanolamine | Escitalopram | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Major | 2 | [
[
[
1466,
25,
318
]
],
[
[
1466,
64,
1230
],
[
1230,
1,
318
]
],
[
[
1466,
6,
5214
],
[
5214,
45,
318
]
],
[
[
1466,
21,
28893
],
[
28893,... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Cital... | Phenylpropanolamine may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Phenylpropanolamine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Escitalopram (Compound)
Phenylpropanolamine (Compound) causes Hallucination (Side E... |
DB09263 | DB13142 | 1,436 | 841 | [
"DDInter1399",
"DDInter274"
] | Patiromer | Calcium glubionate anhydrous | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1436,
24,
841
]
],
[
[
1436,
63,
1152
],
[
1152,
24,
841
]
],
[
[
1436,
63,
1152
],
[
1152,
24,
1252
],
[
1252,
24,
841
]
],
[
[
1436,... | [
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronin... | Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with L... |
DB00938 | DB01100 | 455 | 1,568 | [
"DDInter1635",
"DDInter1470"
] | Salmeterol | Pimozide | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
455,
24,
1568
]
],
[
[
455,
63,
78
],
[
78,
40,
1568
]
],
[
[
455,
63,
1557
],
[
1557,
25,
1568
]
],
[
[
455,
6,
7524
],
[
7524,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interact... |
DB01229 | DB12010 | 973 | 214 | [
"DDInter1377",
"DDInter785"
] | Paclitaxel | Fostamatinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
973,
24,
214
]
],
[
[
973,
25,
976
],
[
976,
24,
214
]
],
[
[
973,
63,
723
],
[
723,
24,
214
]
],
[
[
973,
24,
861
],
[
861,
63,... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacit... | Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may ca... |
DB01211 | DB04868 | 609 | 478 | [
"DDInter393",
"DDInter1293"
] | Clarithromycin | Nilotinib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
609,
25,
478
]
],
[
[
609,
25,
1468
],
[
1468,
63,
478
]
],
[
[
609,
6,
4973
],
[
4973,
45,
478
]
],
[
[
609,
7,
7248
],
[
7248,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"... | Clarithromycin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Clarithromycin (Compound) upreg... |
DB00191 | DB00211 | 73 | 1,290 | [
"DDInter1447",
"DDInter1213"
] | Phentermine | Midodrine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Moderate | 1 | [
[
[
73,
24,
1290
]
],
[
[
73,
24,
1240
],
[
1240,
1,
1290
]
],
[
[
73,
6,
12523
],
[
12523,
45,
1290
]
],
[
[
73,
21,
28741
],
[
28741,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midodrine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxamine"
],
[
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Methoxamine and Methoxamine (Compound) resembles Midodrine (Compound)
Phentermine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Midodrine (Compound)
Phentermine (Compound) causes Agitation (Side Effect) and Agitat... |
DB06186 | DB13007 | 1,439 | 1,060 | [
"DDInter969",
"DDInter642"
] | Ipilimumab | Enfortumab vedotin | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1439,
24,
1060
]
],
[
[
1439,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1439,
63,
14
],
[
14,
24,
1060
]
],
[
[
1439,
64,
1377
],
[
1377,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin ... |
DB00041 | DB09237 | 1,648 | 1,586 | [
"DDInter38",
"DDInter1045"
] | Aldesleukin | Levamlodipine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1648,
24,
1586
]
],
[
[
1648,
24,
1013
],
[
1013,
63,
1586
]
],
[
[
1648,
24,
1486
],
[
1486,
24,
1586
]
],
[
[
1648,
25,
593
],
[
593... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methyl... |
DB00030 | DB01232 | 1,685 | 1,327 | [
"DDInter934",
"DDInter1640"
] | Insulin human | Saquinavir | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
1685,
24,
1327
]
],
[
[
1685,
24,
798
],
[
798,
40,
1327
]
],
[
[
1685,
24,
222
],
[
222,
23,
1327
]
],
[
[
1685,
24,
52
],
[
52,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that ... |
DB00450 | DB14723 | 78 | 159 | [
"DDInter603",
"DDInter1026"
] | Droperidol | Larotrectinib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
78,
24,
159
]
],
[
[
78,
24,
222
],
[
222,
23,
159
]
],
[
[
78,
24,
98
],
[
98,
24,
159
]
],
[
[
78,
64,
1181
],
[
1181,
24,
... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somat... |
DB06372 | DB11581 | 259 | 1,456 | [
"DDInter1594",
"DDInter1926"
] | Rilonacept | Venetoclax | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
259,
24,
1456
]
],
[
[
259,
24,
1129
],
[
1129,
63,
1456
]
],
[
[
259,
63,
1683
],
[
1683,
24,
1456
]
],
[
[
259,
24,
594
],
[
594,
... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Rilonacept may cause a mod... |
DB09061 | DB09122 | 1,627 | 1,613 | [
"DDInter284",
"DDInter1409"
] | Cannabidiol | Peginterferon beta-1a | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1627,
24,
1613
]
],
[
[
1627,
62,
600
],
[
600,
24,
1613
]
],
[
[
1627,
63,
168
],
[
168,
24,
1613
]
],
[
[
1627,
23,
351
],
[
351,
... | [
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
... | Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Bortezom... |
DB00095 | DB04865 | 66 | 4 | [
"DDInter623",
"DDInter1335"
] | Efalizumab | Omacetaxine mepesuccinate | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
66,
24,
4
]
],
[
[
66,
63,
1394
],
[
1394,
24,
4
]
],
[
[
66,
24,
994
],
[
994,
63,
4
]
],
[
[
66,
24,
770
],
[
770,
24,
4... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rituximab"
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Rituximab and Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Risankiz... |
DB00439 | DB06595 | 289 | 1,491 | [
"DDInter341",
"DDInter1214"
] | Cerivastatin | Midostaurin | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
289,
24,
1491
]
],
[
[
289,
24,
112
],
[
112,
23,
1491
]
],
[
[
289,
24,
1017
],
[
1017,
63,
1491
]
],
[
[
289,
24,
663
],
[
663,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib a... |
DB00211 | DB09291 | 1,290 | 741 | [
"DDInter1213",
"DDInter1615"
] | Midodrine | Rolapitant | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
1290,
24,
741
]
],
[
[
1290,
24,
1264
],
[
1264,
24,
741
]
],
[
[
1290,
24,
1264
],
[
1264,
63,
211
],
[
211,
23,
741
]
],
[
[
1290,
... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause... |
DB00009 | DB00945 | 1,271 | 1,479 | [
"DDInter56",
"DDInter20"
] | Alteplase | Acetylsalicylic acid | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
1271,
24,
1479
]
],
[
[
1271,
24,
1338
],
[
1338,
24,
1479
]
],
[
[
1271,
24,
685
],
[
685,
23,
1479
]
],
[
[
1271,
23,
297
],
[
297,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00252 | DB12941 | 362 | 466 | [
"DDInter1460",
"DDInter481"
] | Phenytoin | Darolutamide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Major | 2 | [
[
[
362,
25,
466
]
],
[
[
362,
25,
1374
],
[
1374,
23,
466
]
],
[
[
362,
64,
600
],
[
600,
23,
466
]
],
[
[
362,
24,
86
],
[
86,
23,... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u}... | Phenytoin may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Phenytoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor inter... |
DB08875 | DB13139 | 1,618 | 1,032 | [
"DDInter262",
"DDInter1063"
] | Cabozantinib | Levosalbutamol | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1618,
24,
1032
]
],
[
[
1618,
63,
1220
],
[
1220,
23,
1032
]
],
[
[
1618,
25,
124
],
[
124,
24,
1032
]
],
[
[
1618,
63,
121
],
[
121,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Cabozantinib may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib ... |
DB00959 | DB08907 | 1,486 | 1,344 | [
"DDInter1191",
"DDInter280"
] | Methylprednisolone | Canagliflozin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1486,
24,
1344
]
],
[
[
1486,
24,
549
],
[
549,
1,
1344
]
],
[
[
1486,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
1486,
21,
28873
],
[
28873... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapaglif... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Methylprednisolone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Methylprednisolone (Compound) causes Pan... |
DB00290 | DB00685 | 329 | 1,299 | [
"DDInter219",
"DDInter1887"
] | Bleomycin | Trovafloxacin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Minor | 0 | [
[
[
329,
23,
1299
]
],
[
[
329,
23,
872
],
[
872,
40,
1299
]
],
[
[
329,
21,
28695
],
[
28695,
60,
1299
]
],
[
[
329,
24,
995
],
[
995,
... | [
[
[
"Bleomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Bleomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
... | Bleomycin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Bleomycin (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Trovafloxacin (Compound)
Bleomycin may cause a moderate interacti... |
DB00836 | DB14568 | 543 | 982 | [
"DDInter1088",
"DDInter1000"
] | Loperamide | Ivosidenib | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
543,
24,
982
]
],
[
[
543,
24,
112
],
[
112,
23,
982
]
],
[
[
543,
24,
241
],
[
241,
24,
982
]
],
[
[
543,
63,
867
],
[
867,
24,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and E... |
DB01037 | DB09082 | 1,161 | 659 | [
"DDInter1653",
"DDInter1934"
] | Selegiline | Vilanterol | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1161,
24,
659
]
],
[
[
1161,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1161,
25,
222
],
[
222,
24,
659
]
],
[
[
1161,
24,
959
],
[
959,
... | [
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Selegiline may lead to a major life threatening interaction when taken with Sibutramine and Sibutram... |
DB00451 | DB01045 | 542 | 463 | [
"DDInter1064",
"DDInter1590"
] | Levothyroxine | Rifampicin | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
542,
24,
463
]
],
[
[
542,
24,
690
],
[
690,
40,
463
]
],
[
[
542,
6,
13478
],
[
13478,
45,
463
]
],
[
[
542,
24,
1264
],
[
1264,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Levothyroxine (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Rifampicin (Compound)
Levothyroxine may cause a moderate interaction that could ex... |
DB01208 | DB09322 | 945 | 1,114 | [
"DDInter1705",
"DDInter1966"
] | Sparfloxacin | Zinc sulfate | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Moderate | 1 | [
[
[
945,
24,
1114
]
],
[
[
945,
64,
251
],
[
251,
23,
1114
]
],
[
[
945,
62,
1307
],
[
1307,
23,
1114
]
],
[
[
945,
25,
1220
],
[
1220,
... | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betamethasone"
],
[
"B... | Sparfloxacin may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan may ... |
DB01396 | DB06285 | 1,482 | 65 | [
"DDInter553",
"DDInter1772"
] | Digitoxin | Teriparatide | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of... | Moderate | 1 | [
[
[
1482,
24,
65
]
],
[
[
1482,
40,
1252
],
[
1252,
24,
65
]
],
[
[
1482,
18,
19625
],
[
19625,
46,
504
],
[
504,
23,
65
]
],
[
[
1482,
... | [
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriparatide"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate inte... | Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Teriparatide
Digitoxin (Compound) downregulates CCDC92 (Gene) and CCDC92 (Gene) is upregulated by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interac... |
DB00387 | DB00902 | 1,386 | 104 | [
"DDInter1528",
"DDInter1168"
] | Procyclidine | Methdilazine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1386,
24,
104
]
],
[
[
1386,
24,
13
],
[
13,
24,
104
]
],
[
[
1386,
24,
820
],
[
820,
1,
104
]
],
[
[
1386,
24,
537
],
[
537,
40... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]... | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Alimema... |
DB01324 | DB09045 | 178 | 52 | [
"DDInter1490",
"DDInter607"
] | Polythiazide | Dulaglutide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
178,
24,
52
]
],
[
[
178,
63,
170
],
[
170,
23,
52
]
],
[
[
178,
63,
870
],
[
870,
24,
52
]
],
[
[
178,
1,
674
],
[
674,
24,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone ... |
DB00985 | DB04843 | 1,443 | 1,511 | [
"DDInter562",
"DDInter1149"
] | Dimenhydrinate | Mepenzolate | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1443,
24,
1511
]
],
[
[
1443,
24,
537
],
[
537,
24,
1511
]
],
[
[
1443,
63,
262
],
[
262,
24,
1511
]
],
[
[
1443,
24,
649
],
[
649,
... | [
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and ... |
DB00468 | DB09330 | 1,424 | 985 | [
"DDInter1557",
"DDInter1352"
] | Quinine | Osimertinib | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1424,
25,
985
]
],
[
[
1424,
23,
1247
],
[
1247,
23,
985
]
],
[
[
1424,
24,
1598
],
[
1598,
63,
985
]
],
[
[
1424,
24,
480
],
[
480,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethox... | Quinine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and T... |
DB00188 | DB01611 | 168 | 1,487 | [
"DDInter222",
"DDInter893"
] | Bortezomib | Hydroxychloroquine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
168,
24,
1487
]
],
[
[
168,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
168,
7,
9853
],
[
9853,
57,
1487
]
],
[
[
168,
21,
28658
],
[
28658... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Com... | Bortezomib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Bortezomib (Compound) upregulates TES (Gene) and TES (Gene) is downregulated by Hydroxychloroquine (Compound)
Bortezomib (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroqui... |
DB05679 | DB09074 | 1,683 | 1,362 | [
"DDInter1907",
"DDInter1327"
] | Ustekinumab | Olaparib | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1683,
24,
1362
]
],
[
[
1683,
25,
725
],
[
725,
63,
1362
]
],
[
[
1683,
63,
896
],
[
896,
24,
1362
]
],
[
[
1683,
24,
250
],
[
250,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
],
[
"Satraliz... | Ustekinumab may lead to a major life threatening interaction when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may caus... |
DB01097 | DB15699 | 1,377 | 652 | [
"DDInter1033",
"DDInter232"
] | Leflunomide | Brexucabtagene autoleucel | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
1377,
25,
652
]
],
[
[
1377,
25,
259
],
[
259,
24,
652
]
],
[
[
1377,
24,
1430
],
[
1430,
24,
652
]
],
[
[
1377,
64,
1184
],
[
1184,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonace... | Leflunomide may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Si... |
DB00782 | DB01618 | 1,123 | 776 | [
"DDInter1535",
"DDInter1239"
] | Propantheline | Molindone | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
1123,
24,
776
]
],
[
[
1123,
6,
7992
],
[
7992,
45,
776
]
],
[
[
1123,
21,
28680
],
[
28680,
60,
776
]
],
[
[
1123,
24,
100
],
[
100,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Propantheline",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound... | Propantheline (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Molindone (Compound)
Propantheline (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Molindone (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brom... |
DB01156 | DB01362 | 593 | 497 | [
"DDInter252",
"DDInter960"
] | Bupropion | Iohexol | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
593,
25,
497
]
],
[
[
593,
21,
28681
],
[
28681,
60,
497
]
],
[
[
593,
63,
323
],
[
323,
24,
497
]
],
[
[
593,
24,
819
],
[
819,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by ... | Bupropion (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate disea... |
DB00209 | DB00387 | 352 | 1,386 | [
"DDInter1886",
"DDInter1528"
] | Trospium | Procyclidine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Moderate | 1 | [
[
[
352,
24,
1386
]
],
[
[
352,
40,
11264
],
[
11264,
1,
1386
]
],
[
[
352,
24,
1105
],
[
1105,
1,
1386
]
],
[
[
352,
6,
4304
],
[
4304,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procyclidine"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles ... | Trospium (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Procyclidine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Procyclidine (Compound)
Trospium (Compound) binds CHRM2 (Gene)... |
DB00146 | DB00808 | 160 | 1,605 | [
"DDInter265",
"DDInter916"
] | Calcifediol | Indapamide | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
160,
24,
1605
]
],
[
[
160,
24,
811
],
[
811,
1,
1605
]
],
[
[
160,
24,
1335
],
[
1335,
40,
1605
]
],
[
[
160,
25,
1196
],
[
1196,
... | [
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Calcifediol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
... | Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Calcifediol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Indapamide (Co... |
DB00278 | DB06186 | 291 | 1,439 | [
"DDInter117",
"DDInter969"
] | Argatroban | Ipilimumab | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Major | 2 | [
[
[
291,
25,
1439
]
],
[
[
291,
25,
1468
],
[
1468,
63,
1439
]
],
[
[
291,
25,
4
],
[
4,
24,
1439
]
],
[
[
291,
25,
1409
],
[
1409,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may... | Argatroban may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Argatroban may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccina... |
DB00945 | DB01088 | 1,479 | 714 | [
"DDInter20",
"DDInter908"
] | Acetylsalicylic acid | Iloprost | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1479,
24,
714
]
],
[
[
1479,
23,
539
],
[
539,
62,
714
]
],
[
[
1479,
63,
1638
],
[
1638,
24,
714
]
],
[
[
1479,
24,
318
],
[
318,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
... | Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Iloprost
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Trandolapri... |
DB00526 | DB01599 | 1,555 | 1,232 | [
"DDInter1355",
"DDInter1523"
] | Oxaliplatin | Probucol | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Moderate | 1 | [
[
[
1555,
24,
1232
]
],
[
[
1555,
24,
112
],
[
112,
23,
1232
]
],
[
[
1555,
24,
927
],
[
927,
63,
1232
]
],
[
[
1555,
63,
322
],
[
322,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probucol"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Probucol
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and E... |
DB01232 | DB08875 | 1,327 | 1,618 | [
"DDInter1640",
"DDInter262"
] | Saquinavir | Cabozantinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1327,
25,
1618
]
],
[
[
1327,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
1327,
62,
112
],
[
112,
23,
1618
]
],
[
[
1327,
63,
723
],
[
723,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Saquinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may caus... |
DB00543 | DB01168 | 87 | 1,053 | [
"DDInter82",
"DDInter1526"
] | Amoxapine | Procarbazine | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
87,
25,
1053
]
],
[
[
87,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
87,
24,
126
],
[
126,
23,
1053
]
],
[
[
87,
24,
480
],
[
480,
... | [
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Amoxapine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compou... | Amoxapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Am... |
DB00877 | DB14975 | 629 | 988 | [
"DDInter1678",
"DDInter1949"
] | Sirolimus | Voxelotor | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
629,
24,
988
]
],
[
[
629,
24,
222
],
[
222,
23,
988
]
],
[
[
629,
63,
251
],
[
251,
24,
988
]
],
[
[
629,
24,
985
],
[
985,
24,... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betame... |
DB00690 | DB00792 | 1,216 | 832 | [
"DDInter762",
"DDInter1878"
] | Flurazepam | Tripelennamine | A benzodiazepine derivative used mainly as a hypnotic. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1216,
24,
832
]
],
[
[
1216,
24,
100
],
[
100,
63,
832
]
],
[
[
1216,
24,
649
],
[
649,
1,
832
]
],
[
[
1216,
63,
1594
],
[
1594,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Clofeda... |
DB00193 | DB09020 | 534 | 28 | [
"DDInter1841",
"DDInter212"
] | Tramadol | Bisacodyl | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
534,
24,
28
]
],
[
[
534,
24,
662
],
[
662,
1,
28
]
],
[
[
534,
24,
128
],
[
128,
40,
28
]
],
[
[
534,
18,
20113
],
[
20113,
46,... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine (Compound) resembles Bisac... |
DB00631 | DB15762 | 372 | 725 | [
"DDInter405",
"DDInter1644"
] | Clofarabine | Satralizumab | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
372,
24,
725
]
],
[
[
372,
24,
1362
],
[
1362,
24,
725
]
],
[
[
372,
63,
134
],
[
134,
24,
725
]
],
[
[
372,
64,
1066
],
[
1066,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinor... |
DB00603 | DB00794 | 303 | 759 | [
"DDInter1137",
"DDInter1521"
] | Medroxyprogesterone acetate | Primidone | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
303,
24,
759
]
],
[
[
303,
24,
697
],
[
697,
40,
759
]
],
[
[
303,
63,
362
],
[
362,
1,
759
]
],
[
[
303,
6,
6017
],
[
6017,
45,... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compo... |
DB09237 | DB11978 | 1,586 | 124 | [
"DDInter1045",
"DDInter822"
] | Levamlodipine | Glasdegib | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1586,
24,
124
]
],
[
[
1586,
23,
466
],
[
466,
62,
124
]
],
[
[
1586,
63,
475
],
[
475,
24,
124
]
],
[
[
1586,
24,
159
],
[
159,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Levamlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Mor... |
DB11248 | DB14004 | 1,193 | 398 | [
"DDInter1965",
"DDInter1806"
] | Zinc gluconate | Tildrakizumab | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA. It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wit... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Minor | 0 | [
[
[
1193,
23,
398
]
],
[
[
1193,
62,
58
],
[
58,
24,
398
]
],
[
[
1193,
23,
270
],
[
270,
24,
398
]
],
[
[
1193,
62,
375
],
[
375,
2... | [
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
... | Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab
Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and ... |
DB00353 | DB00668 | 588 | 874 | [
"DDInter1187",
"DDInter652"
] | Methylergometrine | Epinephrine | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Major | 2 | [
[
[
588,
25,
874
]
],
[
[
588,
25,
1636
],
[
1636,
1,
874
]
],
[
[
588,
6,
8374
],
[
8374,
45,
874
]
],
[
[
588,
21,
28956
],
[
28956,
... | [
[
[
"Methylergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
]
],
[
[
"Methylergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
],
[
"Phenyle... | Methylergometrine may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound)
Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Epinephrine (Compound)
Methylergometrine (Compound) causes Palpitations (Side Effe... |
DB01024 | DB01330 | 1,096 | 1,402 | [
"DDInter1252",
"DDInter324"
] | Mycophenolic acid | Cefotetan | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. | Moderate | 1 | [
[
[
1096,
24,
1402
]
],
[
[
1096,
24,
1124
],
[
1124,
1,
1402
]
],
[
[
1096,
24,
1558
],
[
1558,
40,
1402
]
],
[
[
1096,
63,
277
],
[
277,... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotetan"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefotetan (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin and Cefoxitin (Compound) resembles Cefotetan... |
DB00968 | DB08895 | 1,551 | 976 | [
"DDInter1185",
"DDInter1825"
] | Methyldopa | Tofacitinib | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1551,
24,
976
]
],
[
[
1551,
25,
1377
],
[
1377,
25,
976
]
],
[
[
1551,
63,
175
],
[
175,
25,
976
]
],
[
[
1551,
24,
1220
],
[
1220,
... | [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methyldopa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunom... | Methyldopa may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tofacitinib
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may lead to a ma... |
DB00629 | DB09038 | 390 | 1,450 | [
"DDInter844",
"DDInter636"
] | Guanabenz | Empagliflozin | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
390,
24,
1450
]
],
[
[
390,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
390,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
390,
24,
1455
],
[
1455,
... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[... | Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolo... |
DB01097 | DB01268 | 1,377 | 1,151 | [
"DDInter1033",
"DDInter1731"
] | Leflunomide | Sunitinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Major | 2 | [
[
[
1377,
25,
1151
]
],
[
[
1377,
6,
2602
],
[
2602,
45,
1151
]
],
[
[
1377,
18,
8386
],
[
8386,
46,
1151
]
],
[
[
1377,
21,
29662
],
[
29... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Leflunomide",
"{u} (Compound) binds {v} (Gene)",
"PTK2B"
],
[
"PTK2B",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitini... | Leflunomide (Compound) binds PTK2B (Gene) and PTK2B (Gene) is bound by Sunitinib (Compound)
Leflunomide (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound)
Leflunomide (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib... |
DB00204 | DB01064 | 228 | 1,148 | [
"DDInter580",
"DDInter987"
] | Dofetilide | Isoprenaline | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Major | 2 | [
[
[
228,
25,
1148
]
],
[
[
228,
24,
480
],
[
480,
24,
1148
]
],
[
[
228,
21,
29316
],
[
29316,
60,
1148
]
],
[
[
228,
23,
1220
],
[
1220,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoter... | Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Dofetilide (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Isoprenaline (Comp... |
DB00964 | DB06282 | 1,617 | 516 | [
"DDInter110",
"DDInter1053"
] | Apraclonidine | Levocetirizine | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1617,
24,
516
]
],
[
[
1617,
63,
701
],
[
701,
24,
516
]
],
[
[
1617,
24,
407
],
[
407,
63,
516
]
],
[
[
1617,
24,
1688
],
[
1688,
... | [
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
]... | Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Opium and O... |
DB00562 | DB00731 | 1,014 | 1,144 | [
"DDInter188",
"DDInter1269"
] | Benzthiazide | Nateglinide | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1014,
24,
1144
]
],
[
[
1014,
40,
674
],
[
674,
63,
1144
]
],
[
[
1014,
24,
1042
],
[
1042,
63,
1144
]
],
[
[
1014,
24,
870
],
[
870,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u... | Benzthiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a mo... |
DB06718 | DB08886 | 1,687 | 637 | [
"DDInter1709",
"DDInter126"
] | Stanozolol | Asparaginase Erwinia chrysanthemi | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
1687,
24,
637
]
],
[
[
1687,
63,
167
],
[
167,
24,
637
]
],
[
[
1687,
24,
850
],
[
850,
24,
637
]
],
[
[
1687,
24,
1613
],
[
1613,
... | [
[
[
"Stanozolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Stanozolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydr... | Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Stanozolol may cause a moderate interaction that could exacerbate diseases when t... |
DB00598 | DB09132 | 1,523 | 492 | [
"DDInter1013",
"DDInter797"
] | Labetalol | Gadoteric acid | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA). It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). Gadoterate meglumine has one o... | Moderate | 1 | [
[
[
1523,
24,
492
]
],
[
[
1523,
5,
11590
],
[
11590,
44,
1081
],
[
1081,
24,
492
]
],
[
[
1523,
6,
12523
],
[
12523,
45,
1081
],
[
1081,
... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadoteric acid"
]
],
[
[
"Labetalol",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is trea... | Labetalol (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadoteric acid
Labetalol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nicardipine (Compound) ... |
DB00352 | DB04896 | 482 | 901 | [
"DDInter1814",
"DDInter1220"
] | Tioguanine | Milnacipran | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
482,
24,
901
]
],
[
[
482,
21,
28722
],
[
28722,
60,
901
]
],
[
[
482,
24,
292
],
[
292,
63,
901
]
],
[
[
482,
63,
912
],
[
912,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by... | Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Milnacipran (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Milnacipra... |
DB01285 | DB11095 | 708 | 235 | [
"DDInter445",
"DDInter505"
] | Corticotropin | Desirudin | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
708,
25,
235
]
],
[
[
708,
63,
126
],
[
126,
25,
235
]
],
[
[
708,
64,
932
],
[
932,
25,
235
]
],
[
[
708,
24,
4
],
[
4,
25,
... | [
[
[
"Corticotropin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfari... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Desirudin
Corticotropin may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may lead to a major ... |
DB00342 | DB11952 | 1,181 | 800 | [
"DDInter1770",
"DDInter612"
] | Terfenadine | Duvelisib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1181,
24,
800
]
],
[
[
1181,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1181,
25,
11
],
[
11,
24,
800
]
],
[
[
1181,
24,
1213
],
[
1213,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Terfenadine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause... |
DB00983 | DB01035 | 480 | 1,401 | [
"DDInter776",
"DDInter1524"
] | Formoterol | Procainamide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | A derivative of procaine with less CNS action. | Moderate | 1 | [
[
[
480,
24,
1401
]
],
[
[
480,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
480,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
480,
24,
659
],
[
659,... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Formoterol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Formoterol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB00290 | DB00694 | 329 | 51 | [
"DDInter219",
"DDInter485"
] | Bleomycin | Daunorubicin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
329,
24,
51
]
],
[
[
329,
5,
11555
],
[
11555,
44,
51
]
],
[
[
329,
21,
29473
],
[
29473,
60,
51
]
],
[
[
329,
23,
739
],
[
739,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Bleomycin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Diseas... | Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Daunorubicin (Compound)
Bleomycin (Compound) causes Induration (Side Effect) and Induration (Side Effect) is caused by Daunorubicin (Compound)
Bleomycin may cause a minor interaction that can limit clinical effects w... |
DB01059 | DB11057 | 956 | 720 | [
"DDInter1313",
"DDInter1223"
] | Norfloxacin | Mineral oil | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
956,
24,
720
]
],
[
[
956,
24,
927
],
[
927,
63,
720
]
],
[
[
956,
64,
175
],
[
175,
24,
720
]
],
[
[
956,
24,
1151
],
[
1151,
2... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Norfloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone... |
DB00278 | DB00374 | 291 | 1,061 | [
"DDInter117",
"DDInter1852"
] | Argatroban | Treprostinil | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
291,
24,
1061
]
],
[
[
291,
24,
885
],
[
885,
40,
1061
]
],
[
[
291,
21,
28719
],
[
28719,
60,
1061
]
],
[
[
291,
23,
539
],
[
539,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Argatroban (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Treprostinil (Compound)
Argatroban may cause a minor interaction that ... |
DB01244 | DB11581 | 762 | 1,456 | [
"DDInter192",
"DDInter1926"
] | Bepridil | Venetoclax | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
762,
25,
1456
]
],
[
[
762,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
762,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
762,
63,
86
],
[
86,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may c... |
DB09237 | DB12941 | 1,586 | 466 | [
"DDInter1045",
"DDInter481"
] | Levamlodipine | Darolutamide | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
1586,
23,
466
]
],
[
[
1586,
63,
1446
],
[
1446,
23,
466
]
],
[
[
1586,
24,
351
],
[
351,
23,
466
]
],
[
[
1586,
24,
159
],
[
159,
... | [
[
[
"Levamlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
... | Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and ... |
DB00530 | DB11652 | 1,195 | 1,155 | [
"DDInter667",
"DDInter1891"
] | Erlotinib | Tucatinib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1195,
24,
1155
]
],
[
[
1195,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1195,
24,
609
],
[
609,
24,
1155
]
],
[
[
1195,
24,
1320
],
[
1320... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarith... |
DB01394 | DB11730 | 1,554 | 351 | [
"DDInter431",
"DDInter1588"
] | Colchicine | Ribociclib | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1554,
25,
351
]
],
[
[
1554,
63,
112
],
[
112,
23,
351
]
],
[
[
1554,
25,
283
],
[
283,
62,
351
]
],
[
[
1554,
24,
310
],
[
310,
... | [
[
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Colchicine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may ca... |
DB00731 | DB08907 | 1,144 | 1,344 | [
"DDInter1269",
"DDInter280"
] | Nateglinide | Canagliflozin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1144,
24,
1344
]
],
[
[
1144,
24,
549
],
[
549,
1,
1344
]
],
[
[
1144,
6,
17106
],
[
17106,
45,
1344
]
],
[
[
1144,
21,
28681
],
[
286... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Nateglinide (Compound) binds UGT1A9 (Gene) and UGT1A9 (Gene) is bound by Canagliflozin (Compound)
Nateglinide (Compound) causes Hypersensitivity (Side... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.